|1.||Valdivielso, Ángel M: 2 articles (01/2014 - 01/2013)|
|2.||García-López, M Teresa: 2 articles (01/2014 - 01/2013)|
|3.||Herranz, Rosario: 2 articles (01/2014 - 01/2013)|
|4.||Gutiérrez-Rodríguez, Marta: 2 articles (01/2014 - 01/2013)|
|5.||Koppensteiner, Renate: 2 articles (05/2013 - 01/2013)|
|6.||Kopp, Christoph W: 2 articles (05/2013 - 01/2013)|
|7.||Panzer, Simon: 2 articles (05/2013 - 01/2013)|
|8.||Gremmel, Thomas: 2 articles (05/2013 - 01/2013)|
|9.||Steiner, Sabine: 2 articles (05/2013 - 01/2013)|
|10.||Seidinger, Daniela: 2 articles (05/2013 - 01/2013)|
|1.||Glioblastoma (Glioblastoma Multiforme)
01/01/2013 - "Human glioblastoma A172 cells were cultured in the presence of plasmin or the PAR1 specific activating hexapeptide, SFLLRN. "
03/09/1998 - "The presence of the tethered ligand thrombin receptor PAR1 (protease-activated receptor 1) in these cells was demonstrated at the level of receptor binding by using immunofluorescence studies with the monoclonal anti-PAR1 antibody Mab 31-2. Stimulation of human glioblastoma cells both with alpha-thrombin and the thrombin receptor activating peptide TRAP-6 resulted in a series of [Ca+]i spikes as shown by confocal laser fluorescence microscopy with fluo-3 as calcium sensitive fluorescence indicator. "
|2.||Colorectal Neoplasms (Colorectal Cancer)
04/01/2011 - "In this study, we demonstrated that thrombin and the PAR-1 activating peptide (AP) SFLLRN, but not the PAR-4 AP GYPGKF, induced HIF-1α activities, protein expression, and cell motility in colorectal cancer cells, and these actions were significantly inhibited by the PAR-1 antagonist SCH79797. "
|3.||Hypertension (High Blood Pressure)
02/01/1999 - "SFLLRN still induced hypotension in PAR-1(-/-) mice, but HR decrease and secondary hypertension following L-NAME were absent. "
02/01/1999 - "SFLLRN, a nonselective receptor activating peptide caused hypotension and HR decreases in WT mice at 0.3 micromol/kg, as well as secondary hypertension following L-NAME. "
01/01/1998 - "However, L-NAME revealed a rebound hypertension in response to SFLLRN and TFLLRNPNDK but not SLIGRL. "
04/01/2004 - "Our main findings when comparing heart transplant recipients (n = 52) and age- and sex-matched healthy controls (n = 38) were: (i) platelets from heart transplant recipients showed enhanced expression of both P-selectin and CD63 as assessed by flow cytometry; (ii) platelets from these patients also contained significantly increased levels of soluble CD40 ligand and tended to release higher levels of this cytokine upon SFLLRN stimulation as assessed by enzyme immunoassay; (iii) heart transplant recipients had increased levels of soluble P-selectin in platelet-free plasma; and (iv) the enhanced platelet activation after heart transplantation was most pronounced in those with concomitant hypertension. "
12/15/1996 - "Results suggest that alpha-thrombin and TRAP-6 activate at least partially the same intracellular signaling pathways in rat glioma C6 cells, which is evidence for involvement of "tethered ligand" receptor in thrombin induced signaling in glioma C6 cells."
12/15/1996 - "Signaling effects of alpha-thrombin and SFLLRN in rat glioma C6 cells."
11/01/2001 - "Here we have studied the effect of THR and PAR-1-activating peptide (PAR1-AP), SFLLRN, on cytokine-induced expression of inducible nitric oxide (iNOS), a prominent marker of astroglial activation using the rat C6 glioma cells. "
01/01/1997 - "Because the thrombin receptor agonist peptide TRAP-6 also induced inhibition of cell proliferation and the thrombin receptor antagonist peptide T1 prevented the inhibitory effect of alpha-thrombin on C6 glioma cell growth, thrombin receptor involvement in antiproliferative action of alpha-thrombin in C6 glioma cells is highly likely. "
|5.||Coronary Artery Disease (Coronary Atherosclerosis)
11/01/1997 - "We investigated the effects of increasing severity of coronary atherosclerosis on SFLLRN-induced responses on 165 human coronary artery rings isolated fresh from 15 patients who underwent cardiac transplantation. "
01/01/2012 - "Using flow cytometry we observed that JAM-C expression on the surface of washed platelets is increased after activation with thrombin receptor activating peptide-6 in vitro and correlated with platelet-derived P-selectin expression in patients with coronary artery disease (r=0.326, P=0.007). "
10/01/2009 - "The release of APRIL was studied in thrombin receptor (SFLLRN) activated platelets, and the expression of APRIL was examined in plasma and within the atherosclerotic lesion in patients with carotid and coronary atherosclerosis. "
|2.||Thrombin Receptors (Thrombin Receptor)
|4.||2-f)quinazoline-1,3-diamine N3- cyclopropyl- 7- ((4- (1- methylethyl)phenyl)methyl)- 7H- pyrrolo(3
|6.||thrombin receptor peptide SFLLRNP
|9.||CD40 Ligand (CD40L)
|10.||NG-Nitroarginine Methyl Ester (L-NAME)
|2.||Heart Transplantation (Grafting, Heart)
|3.||Transplantation (Transplant Recipients)